Piperacillin as a single agent was compared in a prospective randomized trial with carboxypenicillin-aminoglycoside combinations in empirical therapy of serious bacterial infections. The difference in the clinical response rates with piperacillin (77% of 26 infection episodes) and combination therapy (75% of 24 infection episodes) were not statistically significant. Fewer adverse effects occurred in the piperacillin-treated group (42%) than in the combination-treated group (71%) (P = 0.0399 by Fisher's exact test), although neither nephrotoxicity nor hypokalemia alone was significantly less frequent in patients receiving piperacillin. However, the emergence of resistant organisms during therapy was more frequent among patients receiving piperacillin alone (42% of patients) than among patients receiving combination therapy (17% of patients) (P = 0.0465 by Fisher's exact test). Moreover, emergence of resistance accounted for 5 of 9 patients with treatment failure, superinfection, or both when piperacillin was used as a single agent, compared with 2 of 10 similar patients in the combination group (P = 0.1299 by Fisher's exact test). The use of piperacillin as a single agent in the treatment of serious bacterial infections is not advocated, and the addition of an aminoglycoside to prevent emergence of resistance during empirical therapy of such infections is strongly recommended.
Piperacillin as a single agent was compared in a prospective randomized trial with carboxypenicillin-aminoglycoside combinations in empirical therapy of serious bacterial infections. The difference in the clinical response rates with piperacillin (77% of 26 infection episodes) and combination therapy (75% of 24 infection episodes) were not statistically significant. Fewer adverse effects occurred in the piperacillin-treated group (42%) than in the combination-treated group (71%) (P = 0.0399 by Fisher's exact test), although neither nephrotoxicity nor hypokalemia alone was significantly less frequent in patients receiving piperacillin. However, the emergence of resistant organisms during therapy was more frequent among patients receiving piperacillin alone (42% of patients) than among patients receiving combination therapy (17% of patients) (P = 0.0465 by Fisher's exact test). Moreover, emergence of resistance accounted for 5 of 9 patients with treatment failure, superinfection, or both when piperacillin was used as a single agent, compared with 2 of 10 similar patients in the combination group (P = 0.1299 by Fisher's exact test). The use of piperacillin as a single agent in the treatment of serious bacterial infections is not advocated, and the addition of an aminoglycoside to prevent emergence of resistance during empirical therapy of such infections is strongly recommended.
Carboxypenicillins (such as carbenicillin or ticarcillin) are frequently used in combination with an aminoglycoside in the initial treatment of serious infections. Such a combination offers the potential advantages of an enhanced antibacterial spectrum, possible synergistic activity, and deterrence of bacterial resistance during therapy (21) . However, despite numerous clinical trials, the superiority of combination therapy over monotherapy has not been convincingly demonstrated (21) . The advent of a new piperazinepenicillin, piperacillin, which has remarkable broad-spectrum activity and minimal toxicity, has made the prospect of monotherapy for serious infections particularly attractive. Piperacillin has superior in vitro activity against Pseudomonas, Klebsiella, Enterobacter, indole-positive Proteus, Enterococcus, and Bacteroides species compared with carbenicillin and ticarcillin (2, 7, 13 10 ,ug/ml and trough serum gentamicin levels of <2 ,ug/ml. At the discretion of the investigator, ticarcillin was substituted for carbenicillin or tobramycin was substituted for gentamicin, or both substitutions were made. Antistaphylococcal therapy with cloxacillin was added for either group if clinically indicated. In febrile granulocytopenic patients, trimethoprim-sulfamethoxazole prophylaxis was continued at the discretion of the attending physician in either group.
Treatment was continued until the patient had been afebrile for at least 3 days, unless clinical failure occurred or other specific therapy was deemed necessary.
Laboratory studies. Patients were examined daily during treatment and were followed for 2 weeks thereafter or until they were discharged from the hospital. Cultures of blood and urine, in addition to appropriate cultures from the suspected site of infection, and laboratory measures of renal, hemopoietic, and hepatic function were performed before treatment, every 4 days during treatment, and at 24 to 72 h after completion of treatment. In the case of urinary tract infections, additional urine cultures were obtained at 5 to 9 days and 4 to 6 weeks posttreatment. Serum gentamicin or tobramycin levels were determined at least weekly and as often as clinically indicated by radioimmunoassay (14) . Causative organisms were identified by standard criteria (3, 5, 6, 8-10, 16, 17) . Antimicrobial susceptibility of facultative isolates was determined by the Kirby-Bauer disk diffusion method according to established criteria for each of the study drugs (1, 11) . Antimicrobial susceptibility of obligate anaerobes against carbenicillin, ticarcillin, or piperacillin was determined by either the disk-broth method (19) or the agar-dilution technique (4 
RESULTS
Study patients. Forty-two patients with 54 separate episodes of infection were enrolled in the study. Four episodes were excluded from analysis: one cancer patient with fever and granulocytopenia subsequently proved to have a candida urinary tract infection, and three others died within 72 h of treatment of causes unrelated to bacterial infection (disseminated candidiasis, myocardial infarction, and malignancy, respectively). Of the remaining 50 infection episodes, 26 were treated with piperacillin and 24 were treated with combination therapy. The demographic characteristics, underlying disease, sites of infection and causative organisms, and concomitant therapy were comparable in the two groups (Tables 1 and 2 ). The patients selected for study were seriously ill; more than half had rapidly or ultimately fatal underlying disease (McCabe-Jackson classification) (12) . Pseudomonas aeruginosa was the most common causative organism and 'was isolated in 11 (42%) piperacillin-treated episodes and 8 (33%) combination-treated episodes. Infection was polymicrobial in 12 (46%) piperacillin-treated episodes and 9 (35%) combination-treated episodes. Aerobic gram-positive cocci (including enterococci) VOL. 24, 1983 on October 26, 2017 by guest http://aac.asm.org/ Downloaded from were present in most of these polymicrobial infections.
Bacteremia was documented in two piperacillin-treated and five combination-treated infection episodes before initiation of therapy ( Table  2) . One of these patients in the combinationtreated group had Staphylococcus epidermidis bacteremia associated with an infected venous catheter. She initially responded both clinically and bacteriologically, but later developed a polymicrobial bacteremia (P. aeruginosa, S. epidermidis, and viridans streptococci) when treatment was prematurely discontinued on day 6 because of a suspected toxic reaction to the study drugs. This was considered both a treatment failure and a superinfection. In three other patients with combination therapy, bacteremia developed either during therapy (two patients) or within 24 h after-completion of therapy (one patient). These were considered "breakthrough bacteremias" with the original causative organisms (Escherichia coli, Klebsiella pneumoniae, and Bacteroides melaninogenicus, respectively).
Response to therapy. Clinical response with cure or improvement occurred in 20 (77%) episodes in the piperacillin-treated group and 18 (75%) episodes in the combination-treated group (Table 3) . Clinical failure occurred in six episodes in each group (23% and 25%, respectively). Death due to infection occurred in two patients treated with piperacillin and three patients treated with combination therapy. Among the patients with granulocytopenia at enrollment, clinical cure or improvement occurred in 10 of 12 (83%) piperacillin-treated and 15 of 18 (83%) combination-treated patients. Superinfection developed in five patients treated with piperacillin and four patients treated with combination antibiotics. S. epidermidis complicating intravenous lines and urinary tract infection from enterococci, klebsiellae, enterobacters, or candidae were the most frequent superinfections encountered. Among patients with bacteriologically documented infection, the causative pathogen was eliminated in 52% of the piperacillin-treated group and 59%o of the combination-treated group (Table 3) . Bacteriological failure with persistence of the causative pathogen occurred in eight and five episodes, respectively. P. aeruginosa accounted for five of eight bacteriological failures in the piperacillin-treated group and one of five in the combination-treated group (P = 0.1795 by Fisher's exact test) .
Emergence of resistance. Resistant isolates occurred more frequently during piperacillin thera- Adverse effects. Hypokalemia during antibiotic therapy developed in 7 (27%) patients treated with piperacillin and 10 (42%) patients receiving combination therapy. Serum creatimne rose by 0.5 mg/dl in two (7.6%) patients treated with piperacillin (including one patient with probable interstitial nephritis) and in five (25%) patients receiving combination therapy. These differences were not statistically significant. Other adverse effects included diarrhea (two patients in each treatment group), eosinophilia and skin rash (two and one patients, respectively, in the piperacillin group), and hemolysis and hepatitis (one patient each in the combination group). Overall, 11 of 26 (42%) patients receiving piperacillin and 17 of 24 (71%) patients receiving combination therapy were associated with development of one or more adverse effects (P = 0.0399 by Fisher's exact test).
DISCUSSION
In this study involving a relatively small num-5 (19) 4 (17) ber of patients, no significant difference in clini- patients acquired piperacillin-resistant organisms during piperacillin-amikacin combination therapy.
Another potential disadvantage of the use of piperacillin as a single agent for empirical therapy is its relatively poor activity against Staphylococcus aureus and S. epidermidis (2, 7) . In our prpspective study, addition of anti-staphylococcal therapy was considered clinically indicated in 10 of 26 (38%) patients receiving piperacillin and in 7 of 24 (29%) patients receiving combination therapy. Either S. aureus or S. epidermidis was isolated as a significant pathogen in 14 of 38 (37%) patients with bacteriologically documented infection in this series.
We did not find a significantly lower incidence or less severity of either hypokalemia, bleeding diathesis due to platelet dysfunction, or antibiotic-associated nephrotoxicity in patients treated with piperacillin. However, patients treated with piperacillin alone experienced fewer adverse effects overall compared with patients receiving combination therapy (P < 0.05). The rather high overall incidence (71%) of adverse effects in the combination-treated group was attributed to the frequent occurrence of hypokalemia when carbenicillin was included in the regimen.
Despite its excellent in vitro activity and demonstrated efficacy, use of piperacillin as a single agent in the treatment of serious bacterial infections is not advocated. Addition of an aminoglycoside to prevent emergence of resistance during empirical therapy of such infections is strongly recommended.
